Home » Stocks » CDNA

CareDx, Inc. (CDNA)

Stock Price: $87.51 USD 1.28 (1.48%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $87.50 -0.01 (-0.01%) Jul 29, 5:50 PM
Market Cap 4.49B
Revenue (ttm) 221.21M
Net Income (ttm) -13.58M
Shares Out 51.18M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend $1.58
Dividend Yield 1.80%
Trading Day July 29
Last Price $87.51
Previous Close $86.23
Change ($) 1.28
Change (%) 1.48%
Day's Open 86.21
Day's Range 85.41 - 88.21
Day's Volume 416,984
52-Week Range 29.86 - 99.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

11 hours ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

14 hours ago - GlobeNewsWire

ACROBAT is the prospective multi-center study of AlloHeme, to study the potential of relapse surveillance for stem cell transplant patients ACROBAT is the prospective multi-center study of AlloHeme, to ...

3 days ago - GlobeNewsWire

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

With the trading day more than halfway over, the broad markets were rallying after the carnage on Monday.

Other stocks mentioned: AAPL, VRTX, ARDX, ARRY, IFF, SCPL, VIAV
1 week ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

2 weeks ago - GlobeNewsWire

AlloCare launches in Android Play Store, and is now available on both iOS and Android for all transplant patients AlloCare launches in Android Play Store, and is now available on both iOS and Android fo...

4 weeks ago - GlobeNewsWire

Reg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit Reg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

1 month ago - GlobeNewsWire

Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Research and Development Valantine's ATC Presentation Highlights the Role of AlloMap and AlloSure on Inclusive Resea...

1 month ago - GlobeNewsWire

KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled KOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 pati...

1 month ago - GlobeNewsWire

Transplant physicians to present 40 scientific abstracts, plus two symposia to highlight latest data from multi-center studies on clinical utility of AlloSure Transplant physicians to present 40 scienti...

1 month ago - GlobeNewsWire

Partnership with OrganX to develop decision support systems Partnership with OrganX to develop decision support systems

1 month ago - GlobeNewsWire

With the trading day about halfway over, the markets were sliding, with the tech sector getting the worst of it.

Other stocks mentioned: BE, NTAP, APA, AVB, BLDE, ENPH
1 month ago - 24/7 Wall Street

Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients Study to demonstrate utility of LiverCare post-transplant surveillance for liver transplant recipients

1 month ago - GlobeNewsWire

Participation in Series C and Research Partnership to Advance Development of Bioengineered Transplantable Organs Participation in Series C and Research Partnership to Advance Development of Bioengineere...

2 months ago - GlobeNewsWire

CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement CareDx to share innovations in donor-derived cell-free DNA (dd-cfDNA) and patient engagement

2 months ago - GlobeNewsWire

CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.

Other stocks mentioned: EXAS, GH
2 months ago - The Motley Fool

CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Strong start to 2021, raising full year guidance Strong start to 2021, raising full year guidance

2 months ago - GlobeNewsWire

Renowned transplant clinicians to present 15 heart abstracts at ISHLT Renowned transplant clinicians to present 15 heart abstracts at ISHLT

3 months ago - GlobeNewsWire

Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy Current Medicare coverage for CareDx services remains unchanged under the new universal coverage p...

3 months ago - GlobeNewsWire

Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting Leading transplant clinicians to present data in seven abstract...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

3 months ago - GlobeNewsWire

Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians

3 months ago - GlobeNewsWire

Company to showcase its latest integrated solutions for improving care across the whole transplant journey Company to showcase its latest integrated solutions for improving care across the whole transpl...

3 months ago - GlobeNewsWire

Initial projects underway for global pharmaceutical company Initial projects underway for global pharmaceutical company

3 months ago - GlobeNewsWire

CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program

3 months ago - GlobeNewsWire

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

Other stocks mentioned: NTRA, VCYT
3 months ago - The Motley Fool

CareDx Builds for the Future by Investing in Talent CareDx Builds for the Future by Investing in Talent

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

4 months ago - GlobeNewsWire

This under-the-radar diagnostics company is thriving yet reasonably priced.

Other stocks mentioned: GH
4 months ago - The Motley Fool

TX Connect adds 19,000 patient referrals for kidney transplant and continues CareDx's focus on the patient journey TX Connect adds 19,000 patient referrals for kidney transplant and continues CareDx's f...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

5 months ago - GlobeNewsWire

Benzinga recently spoke with CareDx Inc (NASDAQ: CDNA) CEO Reginald Seeto to discuss the diagnostics surveillance solution provider's business, financials, market opportunity, alliances and future focus...

5 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

5 months ago - GlobeNewsWire

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

5 months ago - GlobeNewsWire

CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentatio...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically...

6 months ago - GlobeNewsWire

Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers Acquisition will build on CareDx's digital capabilities and continue deepening the moat wi...

6 months ago - GlobeNewsWire

CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplan...

6 months ago - GlobeNewsWire

AlloID is a Transplant Patient-Specific Metagenomic Infectious Disease Test Platform, Furthering CareDx's Innovation in Multi-Modality Surveillance Care AlloID is a Transplant Patient-Specific Metagenom...

6 months ago - GlobeNewsWire

CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang CareDx wins a 2-year competitive tender with the French National Blood Service, Établisseme...

6 months ago - GlobeNewsWire

CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind for CareDx.

6 months ago - Seeking Alpha

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

6 months ago - Zacks Investment Research

Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.

Other stocks mentioned: CRWD, MED, MTSI, ZS
6 months ago - Zacks Investment Research

About CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup S... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 17, 2014
CEO
Peter Maag
Employees
456
Stock Exchange
NASDAQ
Ticker Symbol
CDNA
Full Company Profile

Financial Performance

In 2020, CareDx's revenue was $192.19 million, an increase of 51.25% compared to the previous year's $127.07 million. Losses were -$18.71 million, -14.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CareDx stock is "Strong Buy." The 12-month stock price forecast is 100.33, which is an increase of 14.65% from the latest price.

Price Target
$100.33
(14.65% upside)
Analyst Consensus: Strong Buy